CanCure, LLC
dba CanZx Biotherapeutics

Tel: (206) 353-7538
[email protected]

First-in-Class Cancer Immunotherapeutics

New Generation of Cancer-Immunotherapy:
Empower your own immune system to fight cancer

Our goal is to make immunotherapy benefit the majority of cancer patients, not just a few

Jennifer Wu, PhD. President.



Dhar P and Wu JD. NKG2D and its ligands in cancer. Curr Opin Immunol. 2018 Mar 8;51:55-61.  Review current opinion in immunology.pdf

Zhang et al. Antibody-mediated neutralization of soluble MIC significantly enhances CTLA4 blockade therapy. Science Advances, 2017. May 17;3(5):e1602133.  PMID 28560327. Science Advances 2017.  Science Advances 2017.pdf

Jennifer Wu. Antibody targeting soluble NKG2D ligand sMIC refuels and invigorates the endogenous immune system to fight cancer. OncoImmunology 2015 Oct 29;5(3):e1095434. PMID: 27141357.  OncoImmunology 2016.  OncoImmunology 2016.pdf

Shengjun Lu, Jinyu Zhang, Dai Liu, Guangfu Li, Kevin F Staveley-O'Carroll, Zihai Li, and Jennifer Wu. Non-blocking monoclonal antibody targeting soluble MIC revamps endogenous innate and adaptive anti-tumor responses and eliminates primary and metastatic tumors. Clin.Can. Res. 2015, 21:4819-30. PMID 26106076.   Clin Cancer Res-2015-Lu-4819-30.pdf

Fahmin Basher, Hing Wong, Emily Jung, Jennifer Wu. Cooperative anti-tumor effect of soluble MIC neutralizing monoclonal antibody and IL-15 agonists ALT-803 in preclinical animal models. Oncotarget. 2015, 7:814-30. PMID: 26625316.  Oncotarget 2015.pdf

Gang Xiao, Xuanjun Wang, Jun Sheng, Shengjun Lu, Xuezhong Yu and Jennifer D Wu. Soluble NKG2D ligand promotes MDSC expansion and skews macrophage to the alternatively activated phenotype. Journal of Hematology & Oncology, 8:13-23, 2015. PMCID: 25887583.  jhoon-MDSC 2015.pdf

Jinyu Zhang, Fahmin Basher, and Jennifer Wu. NKG2D Ligands in Tumor Immunity: Two Sides of a Coin (Review). NKG2D Ligands in Tumor Immunity: Two Sides of a Coin. Front Immunol. 2015, 6:97-104. PMCID: PMC4349182. 

Gang, Liu, Shengjun Lu, Xuanjuan Wang, Stephanie T. Page, Norman M Greenberg, Celestia Higano, Stephen R. Plymate, Shaolin Sun, Zihai Li and Wu, J. Tumor-derived soluble NKG2D ligand perturbs NK homeostasis and accelerates prostate cancer metastasis. J Clin Invest. 2013. 123(10):4410-22. JCI69369-2013.pdf


López-Soto A. et al. Soluble NKG2D ligands limit the efficacy of immune checkpoint blockade. Oncoimmunology. 2017 Jul 13;6(10):e1346766. PMID 29123961.

Maccalli C et al. Soluble NKG2D ligands are biomarkers associated with the clinical outcome to immune checkpointblockade therapy of metastatic melanoma patients. Oncoimmunology. 2017 May 8;6(7):e1323618. PMID 28811958.

Kumar V, et al., Soluble MICA and a MICA variation as possible prognostic biomarkers for HBV-induced hepatocellular carcinoma. PLoS one. 2012; 7(9):244743. PMID 23024757.

Tamaki S. et al. Soluble MICB serum levels correlate with disease stage and survival rate in patients with oral squamous cell carcinoma. Anticancer Res. 2010;30(10):4097-101. PMID 21036725.

Jinushi M. et al. MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma. Proceedings of the National Academy of Sciences of the United States of America. 2008;105(4):1285-90.

Jinushi M, Hodi FS, Dranoff G. Therapy-induced antibodies to MHC class I chain-related protein A antagonize immune suppression and stimulate antitumor cytotoxicity. Proc Natl Acad Sci U S A. 2006, 103(24):9190-5. PMID 16754847.​

Holdenrieder S. et al.. Soluble MICA in malignant diseases. International journal of cancer Journal international du cancer. 2006;118(3):684-7.

Wu JD., L Higgins, A Steinle, D Cosman, K Haugk, SR Plymate. Prevalent expression of immunostimulatory MIC molecule is counteracted by shedding in prostate cancer. J. Clin. Invest. 2004, 114: 560-568.  JCI 2004.pdf

Groh V, Wu J, Yee C, and Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature. 2002;419(6908):734-738.  nature01112.pdf